64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine
the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to
correctly detect the recurrence of prostate cancer in participants with PSMA-negative
biochemical recurrence of prostate cancer following definitive therapy.